Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib versus rituximab biomarker response trial in multiple sclerosis
2025-523892-50-00Phase 3Authorised
- Sponsor
- Region Stockholm
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple sclerosis (MS) comparing Tolebrutinib arm with Rituximab arm (2 arms). Primary endpoint: Relative change from baseline in CSF neurofilament light chain at 12 months. Planned start Jun 2026; status: authorised.
02
Drugs
tolebrutinibrituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-523892-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523892-50-00.